首页> 外文期刊>Basic & clinical pharmacology & toxicology. >Serum Cytokine Levels of Interleukin-1beta, -6, -8, Tumour Necrosis Factor-alpha and Vascular Endothelial Growth Factor in Breast Cancer Patients Treated with Tamoxifen and Supplemented with Co-Enzyme Q(10), Riboflavin and Niacin.
【24h】

Serum Cytokine Levels of Interleukin-1beta, -6, -8, Tumour Necrosis Factor-alpha and Vascular Endothelial Growth Factor in Breast Cancer Patients Treated with Tamoxifen and Supplemented with Co-Enzyme Q(10), Riboflavin and Niacin.

机译:用他莫昔芬治疗并补充辅酶Q(10),核黄素和烟酸治疗的乳腺癌患者血清IL-1β,-6,-8,肿瘤坏死因子-α和血管内皮生长因子的细胞因子水平。

获取原文
获取原文并翻译 | 示例
           

摘要

The prognostic significance of supplementing co-enzyme Q(10) (CoQ(10)), riboflavin and niacin (CoRN) along with tamoxifen to breast cancer patients was evaluated by measuring the serum cytokine levels of interleukin (IL)-1beta, IL-6, IL-8, tumour necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor. In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg, one dosage per day along with tamoxifen 10 mg twice a day. Serum cytokine levels were elevated in untreated breast cancer patients (Group II) and significantly reduced after tamoxifen therapy for more than 1 year (Group III). When group III breast cancer patients were supplemented with CoRN for 45 days (Group IV) and 90 days (Group V) along with tamoxifen, a significant reduction in cytokine levels were observed (P < 0.05). Such a decrease in serum cytokine levels after CoRN supplementation in breast cancer patients may suggest good prognosisand efficacy of the treatment, and might even offer protection from metastases and recurrence of cancer.
机译:通过测量血清白细胞介素(IL)-1β,IL-的细胞因子水平,评估了补充辅酶Q(10)(CoQ(10)),核黄素和烟酸(CoRN)以及他莫昔芬对乳腺癌患者的预后意义。 6,IL-8,肿瘤坏死因子α(TNF-α)和血管内皮生长因子。在本研究中,将84名乳腺癌患者随机分为每日补充一次CoQ(10)100毫克,核黄素10毫克和烟酸50毫克,每天一次,以及他莫昔芬10毫克,每天两次。在未接受治疗的乳腺癌患者中血清细胞因子水平升高(第二组),在他莫昔芬治疗超过一年后明显降低(第三组)。当III组乳腺癌患者在45天(IV组)和90天(V组)中与他莫昔芬同时补充CoRN时,观察到细胞因子水平显着降低(P <0.05)。乳腺癌患者补充CoRN后血清细胞因子水平的这种降低可能表明该疗法具有良好的预后和疗效,甚至可以提供针对癌症转移和复发的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号